Retiro temprano de esteroides en una cohorte de trasplante renal tratada con tacrolimus, mofetil micofenolato y basiliximab / Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab

Antecedentes: No hay suficiente evidencia sobre la frecuencia de rechazo agudo y la función del injerto en los pacientes con retiro temprano de esteroides (RTE). El objetivo del presente estudio es comparar el efecto del RTE sobre la tasa de filtrado glomerular (TFG), la supervivencia/rechazo del injerto en receptores de una cohorte de tratados con tacrolimus/mofetil micofenolato, comparada con un grupo control. Material y métodos: Cohorte retrospectiva en 60 receptores de bajo riesgo inmunológico entre diciembre de 2005 y julio de 2010. Cohorte del estudio (C-RTE; N = 32), el RTE se hizo el 5o día mientras recibían tacrolimus/mofetil micofenolato. La cohorte control (C-C, N = 28) recibió prednisona/tacrolimus/mofetil micofenolato. Las variables clínicas, bioquímicas e histológicas fueron evaluadas al inicio del estudio, y a los 3, 6 y 12 meses de seguimiento. Se utilizó Kaplan-Meier y el modelo de riesgos proporcionales de Cox para evaluar la supervivencia. Las comparaciones entre cohortes fueron hechas por la t de Student y χ2. Resultados: Durante el seguimiento, la C-C muestra presión sanguínea significativamente mayor tanto sistólica (125 ± 10 frente a 114 ± 8) como diastólica (81 ± 8 frente a 72 ± 7), glucosa sérica (96 ± 13 frente a 86 ± 10), triglicéridos (177 ± 61 frente a 129 ± 34), colesterol total (183 ± 43 frente a 148 ± 34) y colesterol LDL (100 ± 22 frente a 87 ± 25). La C-C presentó una mayor proporción de uso de antihipertensivos (57 frente a 13 %) y de estatinas (27 frente a 9 %). La TFGe fue mejor en la C-RTE que en la C-C (85,4 ± 20,6 frente a 70,6 ± 17,0, p = 0,004). La frecuencia de rechazo agudo fue menor en la C-RTE. Conclusiones: La supervivencia del injerto, la TFG, la tasa de rechazo agudo y el perfil metabólico fueron mejores en la C-RTE que en la C-C (AU)

Background: Acute rejection and graft function have not been completely clarified in early-steroid-withdrawal (ESW) patients. The objective of this study was to compare the effect of early steroid withdrawal on GFR, graft survival/rejection in recipients in a cohort treated with tacrolimus/mycophenolate mofetil compared to a control cohort. Material and method: Retrospective cohort, in 60 low immunological risk recipients between December 2005 and July 2010. Study cohort (ESW-C N=32), steroid withdrawal was carried out after 5 days, while they were receiving tacrolimus/mycophenolate mofetil. The control cohort (C-C, N=28) received prednisone/tacrolimus/mycophenolate mofetil. Clinical, biochemical and histological variables were assessed at baseline and after 3, 6, and 12 months of follow-up. Kaplan-Meier and the Cox proportional hazards model were used to assess survival. Comparisons between cohorts were carried out by the Student's t and χ2 tests. Results: At follow-up, C-C displayed significantly higher systolic (125±10 vs. 114±8) and diastolic (81±8 vs. 72±7) blood pressure, serum glucose (96±13 vs. 86±10), triglycerides (177±61 vs. 129±34), total (183±43 vs. 148±34) and LDL-cholesterol (100±22 vs. 87±25). C-C had a higher proportion of antihypertensive (57 vs. 13%), and statins (27 vs. 9%) use. eGFR was better in ESW-C than in C-C (85.4±20.6 vs. 70.6±17.0, p=.004). AR frequency was lower in ESW-C. Conclusions: Graft survival, GFR, AR rate and metabolic profile were better in the ESW-C than in C-C (AU)

Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab.

BACKGROUND: Acute rejection and graft function have not been completely clarified in early-steroid-withdrawal (ESW) patients. The objective of this study was to compare the effect of early steroid withdrawal on GFR, graft survival/rejection in recipients in a cohort treated with tacrolimus/mycophenolate mofetil compared to a control cohort. MATERIAL AND METHOD: Retrospective cohort, in 60 low immunological risk recipients between December 2005 and July 2010. Study cohort (ESW-C N=32), steroid withdrawal was carried out after 5 days, while they were receiving tacrolimus/mycophenolate mofetil. The control cohort (C-C, N=28) received prednisone/tacrolimus/mycophenolate mofetil. Clinical, biochemical and histological variables were assessed at baseline and after 3, 6, and 12 months of follow-up. Kaplan-Meier and the Cox proportional hazards model were used to assess survival. Comparisons between cohorts were carried out by the Student's t and c2 tests. RESULTS: At follow-up, C-C displayed significantly higher systolic (125 ± 10 vs. 114 ± 8) and diastolic (81 ± 8 vs. 72 ± 7) blood pressure, serum glucose (96 ± 13 vs. 86 ± 10), triglycerides (177 ± 61 vs. 129 ± 34), total (183 ± 43 vs. 148 ± 34) and LDL-cholesterol (100 ± 22 vs. 87 ± 25). C-C had a higher proportion of antihypertensive (57 vs. 13%), and statins (27 vs. 9%) use. eGFR was better in ESW-C than in C-C (85.4 ± 20.6 vs. 70.6 ± 17.0, p=.004). AR frequency was lower in ESW-C. CONCLUSIONS: Graft survival, GFR, AR rate and metabolic profile were better in the ESW-C than in C-C.

[The peritoneal transport type might be distinctive among different Mexican populations on CAPD]. / El tipo de transporte peritoneal puede ser diferente en las distintas poblaciones de pacientes en diálisis peritoneal de México.

INTRODUCTION: The peritoneal equilibration test (PET), standardized by Twardowski et al. more than 20 years ago, is the most common test to classify peritoneal transport. Some reference values from Mexican population were established in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) 10 years ago. The aims of this study were to evaluate the peritoneal transport in a population from the west of Mexico, and compare results with those obtained in the studies of Twardowski and the INCMNSZ. MATERIAL AND METHODS: Cross-sectional study, performed in 156 patients. All consecutive CAPD patients to whom a PET was performed between January 2000 and January 2004 were included. Each patient had a standard PET consistent on infusion of a freshly 2L dialysis exchange at 2.5% after drainage of the previous nocturnal exchange; 3 dialysis aliquots at 0, 2 and 4 hours, and a blood sample at 2 hours, are obtained after infusion. Results were compared to those reported by Twardowski and INCMNSZ. RESULTS: From the total of patients, 48% were diabetics and 62% were men. Mean age was 46 +/- 16 years and body surface area was 1.70 +/- 0.23 m2. There were no differences between groups regarding diabetes and peritonitis. Time on dialysis was shorter in our study than in the INCMNSZ (14.6 +/- 17.8 vs. 20.8 +/- 21.4 months; p < 0.05). Compared to those from Twardowski and INCMNSZ, creatinine D/P ratios at 0, 2 and 4 h of our study were higher, whereas D/D0 ratios at 2 and 4 h, and PET drained volume, were lower. Using reference values obtained in the present study, high transport (H) was present in 18%, high average (HA) in 33%, low average (LA) in 34% and low (L) in 15%, whereas employing the INCMNSZ reference values, H was present in 23%, HA in 36%, LA in 33% and L in 8%. CONCLUSIONS: Patients from this studied population had mean peritoneal transport values higher than those obtained in other studies, including Mexican values. Ideally, it is recommendable to determine reference values in all peritoneal dialysis centers, as extrapolating results from other regions may lead to errors in diagnosing the peritoneal transport type.

[Urological complications after kidney transplantation]. / Complicaciones urológicas postrasplante renal.

BACKGROUND: Urological complications represent a common problem in kidney transplant surgery. The estimated incidence of these complications occurs in 3-30% of renal transplants. Solving these complications may improve renal graft survival and, consequently, patient outcome. The objective is to establish the prevalence of urological complications after renal transplantation. METHODS: We retrospectively reviewed 338 patients with kidney transplantations performed at the Transplant Unit of the Specialties Hospital of the Western Medical Center over a 6-year period. Data were obtained from the patients' clinical files about the prevalence of urological complications and their management. Renal graft loss prevalence and mortality were reported. RESULTS: Overall prevalence of urological complications was 5.92%. Onset time of all complications occurred between 1 and 210 days. Diagnosis was established using clinical, laboratory and imaging methods. Endourological management with double-J catheter through cystoscopy was used as the first option of treatment in the majority of patients, having complete resolution in all cases. There was no graft loss or mortality in our patients. CONCLUSIONS: The most common urological complication was the urinary fistulae located at the ureterovesical anastomosis. In comparison with other transplant centers worldwide, our prevalence of urological complications was similar.

Complicaciones urológicas postrasplante renal / Urological complications after kidney transplantation

BACKGROUND: Urological complications represent a common problem in kidney transplant surgery. The estimated incidence of these complications occurs in 3-30% of renal transplants. Solving these complications may improve renal graft survival and, consequently, patient outcome. The objective is to establish the prevalence of urological complications after renal transplantation. METHODS: We retrospectively reviewed 338 patients with kidney transplantations performed at the Transplant Unit of the Specialties Hospital of the Western Medical Center over a 6-year period. Data were obtained from the patients' clinical files about the prevalence of urological complications and their management. Renal graft loss prevalence and mortality were reported. RESULTS: Overall prevalence of urological complications was 5.92%. Onset time of all complications occurred between 1 and 210 days. Diagnosis was established using clinical, laboratory and imaging methods. Endourological management with double-J catheter through cystoscopy was used as the first option of treatment in the majority of patients, having complete resolution in all cases. There was no graft loss or mortality in our patients. CONCLUSIONS: The most common urological complication was the urinary fistulae located at the ureterovesical anastomosis. In comparison with other transplant centers worldwide, our prevalence of urological complications was similar.